[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tri-Service General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":409},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,51,87,116,144,172,197,223,246,271,297,322,345,368,389],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100637651","phase-4-transversus-abdominis-plane-and-rectus-sheath-block-for-robotic-colectomy-100637651",false,"NCT07624916","Transversus Abdominis Plane and Rectus Sheath Block for Robotic Colectomy","Impact of Transversus Abdominis Plane Block Combined With Rectus Sheath Block on Postoperative Pain Management in Patients Undergoing Elective Robotic Colectomy","Inclusion Criteria:\n\n* Patients scheduled for elective robotic colorectal cancer surgery for the first time\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or age \\> 80 years\n* Allergic to any medication in the protocol\n* Infection over the injection site\n* Chronic pain history\n* Severe hepatic or renal insufficiency\n* Pregnancy\n* Emergency surgery\n* Refusal to join the study","ALL","20 Years","80 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","This study aimed to evaluate the impact of ultrasound-guided bilateral transversus abdominis plane block combined with rectus sheath block on postoperative pain and recovery after robotic colectomy under an enhanced recovery after surgery (ERAS) protocol.",[27,28,29,30,31],"Rectus Sheath Block","Transversus Abdominis Plane Block","Enhanced Recovery After Surgery","Robotic Surgery","Colorectal Cancer",[33,34,35,36,37],"colorectal cancer","robotic colectomy","enhanced recovery after surgery","transversus abdominis plane block","rectus sheath block","NOT_YET_RECRUITING","2026-05-30",{"date":41,"type":42},"2026-06-03","ACTUAL",{"date":44,"type":21},"2026-06-01",{"date":46,"type":21},"2028-03-31",{"name":48,"class":49},"Tri-Service General Hospital","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":50},"100639066","phase-2-tcm-formula-vs-hmb-in-pre-frail-elders-muscle-strength-and-bone-status-100639066","NCT07597850","TCM Formula vs. HMB in Pre-Frail Elders: Muscle Strength and Bone Status","Effects of Traditional Chinese Medicine (TCM) Formula vs. HMB on Muscle Strength and Bone Status in Pre-Frail Elders: A Comparative Study","TCM-HMB-PF","Inclusion Criteria:\n\n* Male or female participants aged 65 years or older at the time of screening.\n* Body Mass Index less than 30 kilograms per square meter.\n* Identified as pre-frail according to the Fried frailty phenotype, meeting 1 to 2 of the following 5 criteria: 1) Hand grip strength below specific thresholds based on gender and Body Mass Index. For males, Body Mass Index 24 or less is 29 kilograms or less, Body Mass Index 24.1 to 28 is 30 kilograms or less, Body Mass Index greater than 28 is 32 kilograms or less. For females, Body Mass Index 23 or less is 17 kilograms or less, Body Mass Index 23.1 to 26 is 17.3 kilograms or less, Body Mass Index 26.1 to 29 is 18 kilograms or less, Body Mass Index greater than 29 is 21 kilograms or less. 2) Slow walking speed. For a 4-meter distance, walking time of 7 seconds or more for males 173 centimeters or shorter, or 6 seconds or more for males taller than 173 centimeters. For females 159 centimeters or shorter, 7 seconds or more, or 6 seconds or more for females taller than 159 centimeters. 3) Self-reported exhaustion. Answering 3 days or more per week to either feeling that everything was an effort or could not get going in the past week. 4) Unintentional weight loss. Loss of 3 kilograms or more or more than 5 percent of body weight in the past year. 5) Low physical activity. Weekly energy expenditure less than 383 kilocalories for males or less than 270 kilocalories for females.\n* Ability to safely complete a 6-meter walk test in a single attempt without assistance or using only simple aids such as a cane.\n* Clinically stable condition allowing for follow-up visits every 4 weeks and participation in all study-related assessments.\n* Willingness to provide existing test data from within 90 days prior to randomization, including Bone Mineral Density by DXA and serum biochemistry or urinalysis results.\n* Sufficient cognitive function to understand the study and sign the informed consent form, or with the assistance of a legal representative.\n* Willingness to maintain existing diet and exercise habits during the study and not start high-intensity exercise programs or large amounts of nutritional supplements.\n\nExclusion Criteria:\n\n* Major acute illness such as acute myocardial infarction, pneumonia, or acute stroke within 2 weeks prior to screening.\n* Major organ dysfunction, including renal function with estimated glomerular filtration rate less than 45 milliliters per minute per 1.73 square meters within 1 month prior to screening, liver function with AST or ALT greater than 3 times the upper limit of normal within 1 month prior to screening, NYHA Class III or IV heart failure, or severe COPD requiring long-term oxygen therapy.\n* Unplanned hospitalization within 1 month prior to screening, or major surgery with incomplete functional recovery within 3 months prior to screening.\n* Current malignant tumor under treatment, or less than 12 months since the completion of cancer treatment.\n* Use of supplements containing the same ingredients as the study interventions, or products that may affect the primary endpoint including HMB, creatine, branched-chain amino acids, or high-dose protein powder within 4 weeks prior to screening.\n* Known significant clinical allergy or hypersensitivity to any components of the study formula or HMB nutritional supplement.\n* Moderate to severe dementia, severe depression, or other psychiatric disorders resulting in inability to cooperate without a legal representative.\n* Participation in other interventional clinical trials involving drugs, biologics, or nutritional supplements within 3 months prior to screening.\n* New initiation or dose adjustment of medications affecting muscle or bone metabolism within 3 months prior to screening, including systemic glucocorticoids, anabolic steroids, testosterone, or growth hormones.\n* Any other condition that, in the opinion of the investigator, makes the participant unsuitable for the study due to safety or compliance concerns.","65 Years",{"count":20,"type":21},[62],"PHASE2","The purpose of this study is to compare the effects of a standardized Traditional Chinese Medicine (TCM) formula versus beta-hydroxy-beta-methylbutyrate (HMB) on muscle strength and bone health in pre-frail older adults . Pre-frailty is a critical stage where functional decline may still be reversed through proper intervention. The study will enroll 90 participants aged 65 years or older who meet the criteria for pre-frailty. Participants will be randomly assigned to either the TCM group (receiving a standardized herbal powder formula) or the HMB group (receiving nutritional supplement tablets) for 24 weeks . The primary objective is to evaluate the change in handgrip strength from baseline to Week 12 . Researchers will also assess changes in skeletal muscle mass, bone mineral density, and overall physical performance . The goal is to determine if the TCM formula is an effective alternative or complementary intervention for managing geriatric frailty.",[65,66,67,68,69],"Pre-Frailty","Sarcopenia","Muscle Atrophy or Weakness","Osteoporosis","Aging",[71,72,73,74,75,76,77],"Traditional Chinese Medicine","HMB (Hydroxy-beta-methylbutyrate)","Muscle Strength","Handgrip Strength","Body Composition","Elderly Health","Randomized Controlled Trial","RECRUITING","2026-05-13",{"date":81,"type":42},"2026-05-19",{"date":83,"type":42},"2026-04-02",{"date":85,"type":21},"2026-12-31",{"name":48,"class":49},{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":95,"targetDuration":4,"studyType":22,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":50},"100638671","comparative-observation-of-metabolic-and-pharmacologic-adipose-remodeling-with-enhanced-incretin-agonists-100638671","NCT07589322","Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs","Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study","COMPARE-AT","Inclusion Criteria:\n\n* Age 20-65 years.\n* BMI ≥27 kg\u002Fm² with metabolic syndrome (ATP III or IDF criteria).\n* Stable background medications (antihypertensives, statins, etc.) for ≥3 months.\n* Able and willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* History of diabetes; history of pancreatitis; personal\u002Ffamily history of medullary thyroid carcinoma or MEN2.\n* eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m², decompensated liver disease, NYHA class III-IV heart failure.\n* Recent (\\\u003C3 months) acute coronary syndrome, stroke, or coronary revascularization.\n* Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months.\n* Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).",{"count":96,"type":21},120,[98],"NA","This randomized, open label, head to head clinical trial directly compares tirzepatide and semaglutide in adults with obesity and metabolic syndrome (N=120, age 20-65, 1:1 randomization). Participants undergo deep phenotyping at baseline, 6 months, and 12 months, including DXA (regional fat, lean mass, and BMD), MRI PDFF (liver fat), 7 site skinfold thickness, grip strength, fasting biochemistry, and AI processed 12 lead ECGs. Centralized biobanking of serum, plasma, and PBMCs enables targeted and discovery multi omic analyses.",[101],"Obesity and Metabolic Syndrome",[103,104,105,106,107],"tirzepatide","semaglutide","obesity","metabolic syndrome","multi omic","2026-05-10",{"date":110,"type":42},"2026-05-15",{"date":112,"type":42},"2026-03-31",{"date":114,"type":21},"2029-09-30",{"name":48,"class":49},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":123,"sex":16,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},"100632577","effectiveness-of-intensive-tutoring-vs-flexible-self-learning-on-digital-health-literacy-and-self-efficacy-for-my-health-bank-app-use-among-adults-over-50-100632577","NCT07515495","Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for \"My Health Bank\" App Use Among Adults Over 50","Effectiveness of Intensive Tutoring vs. Flexible Self-Learning on Digital Health Literacy and Self-Efficacy for \"My Health Bank\" App Use Among Adults Over 50: A Randomized Controlled Trial Using AI-Co-Created Materials","Inclusion Criteria:\n\n* Participants aged 50 years and older.\n* Possession of a smartphone with basic operational skills (e.g., unlocking the phone, making calls, and using LINE).\n* Self-reported lack of familiarity with the \"My Health Bank\" App (used less than 3 times or never used in the past year).\n* Proficiency in listening, speaking, reading, and understanding Mandarin Chinese.\n\nExclusion Criteria:\n\n* Regular users of the \"My Health Bank\" App (used 3 times or more in the past year).\n* Severe cognitive impairment identified through brief cognitive screening, the participant unable to follow instructions or complete questionnaires.\n* Smartphone operating system is too outdated to support the installation of the \"NHI App\" (National Health Insurance App).\n* Inability to complete the App download and installation process independently or with family assistance (e.g., lost App Store\u002FGoogle Play password, insufficient storage space).",true,"50 Years",{"count":126,"type":21},235,[98],"The purpose of this study is to evaluate the effectiveness of two different educational models in improving the use of the \"My Health Bank\" App (a Personal Health Record system in Taiwan) among adults aged 50 and older. As Taiwan's population ages, digital health management has become essential, yet older adults often face a \"digital divide.\" Participants will be randomly assigned to either a \"Intensive Guided Learning group\" (receiving one-on-one human instruction) or a \"Flexible Self-study group\" (using self-learning materials co-created with Generative AI). The study aims to compare the outcomes of these two groups in terms of enhancing digital health literacy, self-efficacy, and actual App usage behavior to identify more effective and scalable digital health education strategies.",[130,131],"Digital Health Literacy","Healthy Aging",[133,134,135,77],"eHealth Literacy","Health Self-Efficacy","My Health Bank","2026-04-07",{"date":138,"type":42},"2026-04-13",{"date":83,"type":42},{"date":141,"type":21},"2027-03-09",{"name":48,"class":49},2,{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":4,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":59,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":50},"100618112","to-investigate-the-change-of-brain-and-autonomic-function-from-different-protocols-of-repeated-transcranial-magnetic-stimulation-therapy-for-patients-with-post-traumatic-stress-disorder-comorbid-major-depressive-disorder-100618112","NCT07327385","To Investigate the Change of Brain and Autonomic Function From Different Protocols of Repeated Transcranial Magnetic Stimulation Therapy for Patients With Post-traumatic Stress Disorder Comorbid Major Depressive Disorder","The Pathophysiological Mechanisms and Novel Treatments Linking Stress and Mental Health Conditions -To Investigate the Change of Brain and Autonomic Function From Different Protocols of Repeated Transcranial Magnetic Stimulation Therapy for Patients With Post-traumatic Stress Disorder Comorbid Major Depressive Disorder: a Randomized, Double-blind, Crossover Study","Inclusion Criteria:\n\n1. Adults aged 18 to 65 years.\n2. Clinical diagnosis of posttraumatic stress disorder (PTSD) according to DSM-5 criteria, confirmed by a board-certified psychiatrist.\n3. Presence of comorbid major depressive disorder with stable clinical condition.\n4. PTSD symptom severity defined as: PTSD Checklist for DSM-5, Chinese version (C-PCL-5) total score ≥ 31.\n5. Depressive symptom severity defined as: Patient Health Questionnaire-9 (PHQ-9) total score ≥ 10.\n6. Stable psychiatric medication regimen for at least 4 weeks prior to enrollment, or medication-free.\n7. Ability to understand the study procedures and provide written informed consent.\n8. Normal or corrected-to-normal vision and hearing.\n9. Ability to comply with study procedures and visit schedule.\n\nExclusion Criteria:\n\n1. Lifetime diagnosis of schizophrenia spectrum disorders, bipolar disorder, or pervasive developmental disorders.\n2. Alcohol or substance use disorder (excluding caffeine and nicotine) within the past 6 months.\n3. Ongoing trauma-focused psychotherapy during the study period.\n4. Prior exposure to repetitive TMS treatment exceeding five sessions.\n5. Current or recent (within the past year) suicidal ideation or behavior, defined as: PHQ-9 item 9 score ≥ 1, confirmed by clinical psychiatric evaluation.\n6. Self-injurious behavior requiring medical attention within the past 3 months.\n7. History of epilepsy, seizure disorder, or family history of epilepsy.\n8. Significant neurological disorders, severe traumatic brain injury, or history of brain surgery.\n9. Presence of implanted metallic or electronic medical devices (e.g., pacemakers, cochlear implants, neurostimulators).\n10. Uncontrolled major medical illnesses or severe cardiovascular disease.\n11. Pregnancy or breastfeeding.\n12. Skin lesions or infections at the stimulation site.\n13. Use of medications known to significantly lower seizure threshold (e.g., tricyclic antidepressants or certain analgesics).\n14. Any condition deemed by the investigator to render the participant unsuitable for rTMS.","18 Years",{"count":153,"type":21},50,[98],"This study aims to investigate the immediate neurophysiological and autonomic effects of two noninvasive brain stimulation protocols-prolonged intermittent theta-burst stimulation (prolonged iTBS) and high-frequency repetitive transcranial magnetic stimulation (HF-rTMS)-in patients with posttraumatic stress disorder (PTSD) comorbid with major depressive disorder (MDD). Using a randomized, double-blind, sham-controlled crossover design, changes in prefrontal cortical activity measured by functional near-infrared spectroscopy (fNIRS) and autonomic nervous system function measured by heart rate variability (HRV) will be assessed before and immediately after a single stimulation session.",[157,158],"Posttraumatic Stress Disorder (PTSD)","Depression - Major Depressive Disorder",[160,161,162,163],"PTSD","functional near-infrared spectroscopy","Heart Rate Variability; HRV","rTMS","2026-02-11",{"date":166,"type":42},"2026-02-17",{"date":168,"type":21},"2026-02-09",{"date":170,"type":21},"2028-12-31",{"name":48,"class":49},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":123,"sex":16,"minAge":151,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":22,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":50},"100620238","ai-enabled-electrocardiogram-guided-guideline-directed-medical-therapy-on-incident-left-ventricular-dysfunction-a-target-trial-emulation-study-100620238","NCT07355023","AI-Enabled Electrocardiogram-Guided Guideline-Directed Medical Therapy on Incident Left Ventricular Dysfunction: A Target Trial Emulation Study","Inclusion Criteria:\n\n* With an ECG followed by an echocardiogram within a 90-day interval\n* With preserved left ventricular ejection fraction (LVEF ≥ 50%)\n\nExclusion Criteria:\n\n* missing essential variables or ECG lead data\n* any prior LVEF \\\u003C 50%\n* loss to follow-up or death during the 90-day assessment window",{"count":179,"type":21},5000,[98],"This multicenter retrospective study evaluates whether artificial intelligence-enabled electrocardiography (AI-ECG) can identify individuals at high risk for left ventricular dysfunction and whether targeted guideline-directed medical therapy can mitigate subsequent risk. Using a large multicenter cohort of patients with preserved left ventricular systolic function, the investigators applied an AI-ECG-based risk stratification approach and emulated a target trial to examine the association between guideline-directed therapies and the risk of incident left ventricular functional decline.",[183],"Left Ventricular (LV) Systolic Dysfunction",[185,186,187,188],"Artificial intelligence","Electrocardiogram","Deep learning","Left ventricular dysfunction","2026-01-12",{"date":191,"type":42},"2026-01-21",{"date":193,"type":21},"2026-01-01",{"date":195,"type":21},"2026-01-15",{"name":48,"class":49},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":50},"100611484","antrodia-cinnamomea-extract-effects-on-lung-cancer-patients-quality-of-life-during-chemotherapy-100611484","NCT07241182","Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy","The Effects of Antrodia Cinnamomea Fruiting Body Extract on Quality of Life and Chemotherapy Side Effects in Patients With Lung Cancer Undergoing Platinum-Based Chemotherapy","Inclusion Criteria:\n\n* Pathologically and radio-graphically diagnosed lung cancer\n* Age greater than 18 years\n* Received platinum-based chemotherapy\n* Life expectancy of six months or longer\n\nExclusion Criteria:\n\n* Inability to comply with timely supplementation administration.\n* Within 14 days prior to trial entry, laboratory data showing abnormal liver function, abnormal kidney function\n* Within 30 days prior to trial entry, unexplained fever ≥38.5°C for 7 consecutive days or chronic diarrhea for 15 consecutive days.\n* Currently receiving hormone therapy.\n* Major cardiac disease or arrhythmia severe enough that the attending physician considers the patient unsuitable for trial participation.\n* Major neuropathy.\n* Patients with currently active acute infections.\n* Patients with known allergies\u002Fallergic reactions to the investigational product or any components in their formulations.\n* Patients currently taking supplements containing Antrodia camphorata extract.","99 Years",{"count":206,"type":21},40,[98],"This randomized trial will test whether Antrodia cinnamomea supplement improves quality of life in lung cancer patients receiving platinum-based chemotherapy.\n\nParticipants at Tri-Service General Hospital will be randomized to receive either Antrodia cinnamomea capsules or placebo for 3 months, with follow-up to 6 months (24 weeks). Primary outcomes include nausea\u002Fvomiting scores, sleep quality, quality of life, and cancer symptoms.",[210],"Lung Cancer (Diagnosis)",[212,213,214],"Chemotherapy side effects","Lung cancer","Antrodia cinnamomea","2026-01-05",{"date":217,"type":42},"2026-01-08",{"date":219,"type":42},"2025-11-24",{"date":221,"type":21},"2027-09-30",{"name":48,"class":49},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":236,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":50},"100587763","comparing-the-efficacy-of-lyophilized-self-growth-factor-versus-prp-injection-for-knee-oa-100587763","NCT06932614","Comparing the Efficacy of Lyophilized Self Growth Factor Versus PRP Injection for Knee OA","Comparing the Efficacy of Lyophilized Self Growth Factor Versus Platelet-Rich Plasma(PRP) Injection for Knee Osteoarthritis: A Prospective, Double-Blind, Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female, aged over 20 and under 80.\n* Consciousness clear and able to communicate.\n* Unilateral or bilateral osteoarthritis of the knee with symptoms lasting more than 3 months.\n* X-ray imaging shows mild to moderate knee osteoarthritis (Kellgren-Lawrence grades 1-3).\n* Knee joint pain with a Visual Analogue Scale (VAS) score greater than 4.\n\nExclusion Criteria:\n\n* Severe knee osteoarthritis (Kellgren-Lawrence grade 4).\n* Currently systemic infection.\n* Received hyaluronic acid or corticosteroid intraarticular injections within the past six months, or received NSAIDs or oral corticosteroid treatment within 7 days prior to treatment.\n* The treated joint has undergone joint replacement surgery or major surgery.\n* Severe knee deformity or instability.\n* Known history of cancers, rheumatoid arthritis, platelet dysfunction, thrombocytopenia, hypofibrinogenemia, acute or chronic infectious diseases, chronic liver disease, or poorly controlled cardiovascular disease or diabetes.\n* Currently receiving anticoagulant therapy.\n* Long-term or excessive use of aspirin or vitamin E.\n* History of HIV\u002FAIDS, syphilis, or other legally notifiable infectious diseases.\n* Pregnant or breastfeeding women, or women and men of childbearing potential who are unable to use effective contraception during the treatment period.\n* Deemed unsuitable for participation in the trial by the principal investigator.\n* Unable to sign the informed consent form.",{"count":20,"type":21},[98],"Knee osteoarthritis(OA) is a common degenerative joint disease that often leads to knee pain, stiffness, and a decline in quality of life among middle-aged and elderly individuals. Platelet-rich plasma (PRP) is a regenerative treatment method that involves drawing a small amount of the patient's own blood and using centrifugation process to produce PRP. PRP, which is rich in growth factors and anti-inflammatory cytokines, facilitate the repair of damaged tissues and has been used in treating knee OA. Self-repair factor (SRF), an advanced form of PRP, is created using multi-step centrifugation and proprietary processes to increase platelet concentration. This enhancement may offer superior repair efficacy and faster recovery compared to traditional PRP. To explore this potential, we designed a randomized, double-blind, clinical trial to compare the effectiveness of SRF and PRP in treating degenerative knee osteoarthritis.",[234,235],"Knee Osteoarthritis","PRP Injection",[234,237],"PRP injection","2025-09-03",{"date":240,"type":42},"2025-09-10",{"date":242,"type":42},"2025-08-01",{"date":244,"type":21},"2026-07-31",{"name":48,"class":49},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":267,"leadSponsor":269,"locationsCount":270},"100595866","external-validation-of-artificial-intelligence-enabled-electrocardiography-ai-ecg-for-the-detection-of-left-ventricular-dysfunction-lvd-100595866","NCT07038018","External Validation of Artificial Intelligence-enabled Electrocardiography (AI-ECG) for the Detection of Left Ventricular Dysfunction (LVD)","External Validation of Artificial Intelligence-Enabled Electrocardiograms for the Detection of Reduced Left Ventricular Ejection Fraction","Inclusion Criteria:\n\n* patients with ECGs and an echocardiogram within 7 days\n\nExclusion Criteria:\n\n* Missing ECG signals\n* Missing LVEF assessment in echocardiograms","100 Years",{"count":255,"type":21},12500,"OBSERVATIONAL","This is a multi-center, retrospective study evaluating the performance of an artificial intelligence-enabled electrocardiography (AI-ECG) algorithm in detecting reduced left ventricular ejection fraction (LVEF ≤ 40%). All included patients from participating hospitals must have undergone a digital 12-lead electrocardiogram (ECG) and an echocardiogram with assessment of LVEF within seven days. The AI-ECG algorithm will be applied to evaluate its diagnostic performance, which will be further assessed across subgroups stratified by demographic characteristics and clinical factors.",[259],"Cardiac Disease",[261,262],"left ventricular dysfunction","artificial intelligence","2025-06-25",{"date":265,"type":42},"2025-06-26",{"date":242,"type":21},{"date":268,"type":21},"2025-09-30",{"name":48,"class":49},13,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":123,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":284,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":50},"100578714","effects-of-wearable-devices-initiates-behavioral-change-intervention-on-body-composition-physical-activity-sleep-quality-and-stress-of-nurses-in-hospital-working-place-100578714","NCT06814886","Effects of Wearable Devices Initiates Behavioral Change Intervention on Body Composition, Physical Activity, Sleep Quality and Stress of Nurses in Hospital Working Place","Effects of Wearable Devices Initiates Behavioral Change Intervention on Body Composition, Physical Activity, Sleep Quality and Stress of Nurses in Hospital Working Place: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals who give informed consent for this study and are 20 years old or older.\n* Those who own a smartphone and are willing to join the study's LINE group.\n* Individuals whose mobile application (APP) can synchronize with the Fitbit Charge 6 wearable device.\n* Nurses who hold a nursing license and are working in a clinical setting.\n\nExclusion Criteria:\n\n* Individuals unable to provide informed consent for this study and are younger than 20 years old.\n* Those who do not own a smartphone.\n* Individuals who do not have a nursing license or are not employed in a clinical setting as a nurse.\n* Participants who are already involved in other health promotion or exercise training studies.\n* Nurses who are currently pregnant.",{"count":96,"type":21},[98],"Background: Physically inactive and poor sleep quality are at increased risk for non-communicable diseases. Nurses were the most vulnerable inactive healthcare personnel who may not meet global physical activity recommendations because of complicated rotation shifts and heavy working loading. Wearable devices initiate behavior intervention combined with smartphone applications could offer new opportunities for social connection by a convenient way for nurses to improve physical activity and sleep quality.\n\nObjectives: To evaluate the effects of wearable devices initiate behavioral intervention on body composition, physical activity, sleep quality and stress of nurses in hospital working place.\n\nMethod: This is a randomized controlled trial that will recruit 120 nurses and randomly assign them into two groups from a hospital working place. The nurses in the intervention group will receive 12-week wearable devices to initiate behavioral intervention. The nurses in the comparison group will only receive 12-week wearable devices monitoring. Data will be collected at baseline and 12-week and 24-week follow-up. The body composition will be measured by bioelectrical impedance analysis (BIA). The physical activity and sleep quality will be monitored by the Fitbit wearable device and application. The mediator parameter of the stress will be measured by salivary amylase activity (SAA). We will control the internal validity to assure the quality of training, treatment fidelity, identify barriers and facilitators of implementation, and assess participants' satisfaction. General estimating equations (GEE) will be applied to examine the effects of time and group interaction.",[282,283],"Nurse","Healthy Adult",[285,286,287,288],"wearable device","behavioral change intervention","nurse","working place","2025-06-18",{"date":291,"type":42},"2025-06-24",{"date":293,"type":42},"2025-05-01",{"date":295,"type":21},"2027-03-01",{"name":48,"class":49},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":307,"briefSummary":308,"conditions":309,"keywords":312,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":320,"leadSponsor":321,"locationsCount":4},"100574629","combined-corticosteroid-injections-and-shockwave-therapy-for-sacroiliac-joint-pain-100574629","NCT06761768","Combined Corticosteroid Injections and Shockwave Therapy for Sacroiliac Joint Pain","Efficacy of Combining Corticosteroid Injections and Extracorporeal Shockwave Therapy in Patients With Sacroiliac Joint Pain","Inclusion Criteria:\n\n* Low back pain lasting for 3 months or more\n* Pain VAS score of 4 or higher\n* Three or more positive results in sacroiliac joint provocation tests\n* At least 50% pain relief following ultrasound-guided sacroiliac joint injection with local anesthetic\n\nExclusion Criteria:\n\n* Currently undergoing extracorporeal shockwave therapy in other areas\n* Suspected pain caused by other lumbar spine or hip joint conditions (e.g., lumbar spine or disc disorders, radicular pain, spondylolisthesis\u002Fdisc degeneration, hip arthritis)\n* Presence of complex comorbidities, including trauma, systemic infections (e.g., fever, chills, night sweats), local sacroiliac joint infections, autoimmune diseases, or immunosuppression\n* Sacroiliac joint injection therapy received within the past 6 months\n* Contraindications for extracorporeal shockwave therapy (e.g., cancer or current\u002Fprior infections at the treatment site, pacemakers, pregnancy, epilepsy, or coagulation disorders caused by disease or medication)\n* Impaired renal function preventing the administration of contrast agents for sacroiliac joint bone scanning","75 Years",{"count":306,"type":21},44,[98],"This study aims to investigate the combined use of corticosteroid injections and ESWT for SIJ pain.",[310,311],"Sacroiliac Joint Dysfunction","Sacroiliac Joint Pain",[310,313,314,315],"Sacroiliac joint pain","Steroid Injection","Extracorporeal shock wave therapy","2025-01-07",{"date":318,"type":42},"2025-01-09",{"date":242,"type":21},{"date":244,"type":21},{"name":48,"class":49},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":123,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":328,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":50},"100555207","the-combined-utility-of-angio-ct-and-mri-in-managing-chronic-musculoskeletal-pain-a-prospective-study-to-evaluate-the-efficacy-of-transarterial-microembolization-100555207","NCT06509087","The Combined Utility of Angio-CT and MRI in Managing Chronic Musculoskeletal Pain: a Prospective Study to Evaluate the Efficacy of Transarterial Microembolization","Inclusion Criteria:\n\n* Patients with chronic musculoskeletal shoulder or knee joint pain in our hospital, including degenerative knee arthritis, adhesive capsulitis of the shoulder, and those confirmed by physical examination or ultrasound-guided injection to have tendinopathy or ligamentopathy, who have failed drug therapy, rehabilitation, or injection treatments, with a duration of symptoms greater than three months, are the target population of this study.\n\nExclusion Criteria:\n\n* Pregnancy, coagulation disorders, symptoms of relevant local infections or tumors, and patients allergic to contrast agents. Patients must have complete medical records; those who do not meet the inclusion criteria will be excluded.",{"count":329,"type":21},60,"Transarterial microembolization (TAME) is a novel treatment option for chronic musculoskeletal pain, especially suitable for patients who have not responded to conservative treatment or are unsuitable for surgical procedures. This minimally invasive technique primarily targets abnormal neovascularization for embolization, relying heavily on precise information provided by various imaging techniques to ensure the effectiveness and safety of the treatment. This study aims to explore the application of integrating preoperative magnetic resonance imaging (MRI) evidence of patient pain and intraoperative high-resolution synchronous imaging information from fused computed tomography (CT) and angiography systems. This integration is intended to enhance preoperative planning, intraoperative guidance, and final treatment outcome assessment, focusing on its crucial contribution to treatment success. It is hoped that this approach will provide pain intervention physicians with reliable diagnostic tools and safe treatment methods, thereby improving treatment outcomes for patients with chronic musculoskeletal pain.",[332,333,334,335,336],"Chronic Musculoskeletal Disease","Transarterial Embolization","Magnetic Resonance Imaging","Angiography","Computed Tomography","2024-08-27",{"date":339,"type":42},"2024-08-28",{"date":341,"type":42},"2024-07-25",{"date":343,"type":21},"2027-07-31",{"name":48,"class":49},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":16,"minAge":151,"maxAge":4,"enrollmentInfo":353,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":355,"conditions":356,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":50},"100558694","post-surgical-multimodal-analgesia-with-oral-strong-opioids-100558694","NCT06554457","Post Surgical Multimodal Analgesia With Oral Strong Opioids","Study on the Clinical Effectiveness of Oral Strong Opioids for Common Orthopedic Surgeries Following Multimodal Analgesia","ORORA","Inclusion Criteria:\n\n1. Aged 18 or older\n2. Must undergo one of the following treatments:\n\n(1) Fracture of upper or lower limbs or pelvis requiring internal fixation surgery (2) Spinal fusion surgery (3) Joint replacement surgery 3. Requiring multimodal analgesics for postoperative pain control, with oral strong opioids as the primary opioid analgesic, as assessed by his\u002Fher physician.\n\n4\\. Voluntarily sign the informed consent form and agree to the collection of clinical questionnaires and medical-related information for this study.\n\nExclusion Criteria:\n\n1. Patients who have not received any or have only received oral potent opioids for no more than 1 day during the postoperative hospitalization period (including those known to be intolerant or allergic to opioid medications).\n2. Patients who have received or are expected to use long-acting opioid injections within 7 days before surgery or during the postoperative hospitalization period.\n3. Patients who use patient-controlled analgesics for pain control after surgery.\n4. Patients with a history of substance abuse or who require continuous treatment with other opioid receptor agonists or antagonists (such as naloxone or methadone).\n5. Patients with a history of mental illness who continue to require medication control from 28 days before surgery and until discharge.\n6. Other cases deemed ineligible by the study investigator.",{"count":354,"type":21},200,"This is a prospective observational case study, focusing on the clinical effectiveness of oral strong opioids for pain management following common orthopedic surgeries.The study aims to evaluate the effectiveness of multimodal analgesia with oral strong opioids, reduce common opioid-related side effects, and improve patient compliance and satisfaction.",[357,358,359],"Orthopedic Procedures","Arthroplasty","Fracture Fixation","2024-08-14",{"date":362,"type":42},"2024-08-15",{"date":364,"type":21},"2024-08-12",{"date":366,"type":21},"2025-07-31",{"name":48,"class":49},{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":373,"acronym":4,"eligibilityCriteria":374,"healthyVolunteers":123,"sex":375,"minAge":4,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":256,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":50},"100514651","a-study-on-the-bone-health-effectiveness-of-applying-recombinant-factor-viii-fc-rfviiifc-to-patients-with-hemophilia-a-prototype-a-100514651","NCT05981274","A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","A Prospective and Retrospective Interventional Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)","Inclusion Criteria:\n\n1. Patients with severe hemophilia A (all ages).\n2. Patients with moderate type hemophilia A with hemophilic arthropathy.\n3. Currently on rFVIIIFc regular prophylaxis and have previous medical record with regular prophylaxis with standard half-life product for one year\n4. Able and willing to undergo joint and bone examinations\n\nExclusion Criteria:\n\n1. Participants of other interventional studies.\n2. Patients with current inhibitors.\n3. History of major neurological disease (eg. Stroke, Parkinson's disease, neuropathy, etc.)\n4. History of major psychiatric disease (eg. Schizophrenia, bipolar disorder)\n5. Significantly impaired vision\u002Fhearing","MALE",{"count":377,"type":21},45,"Study Objectives\\*\n\n1. Provide a systematic evaluation of the treatment outcomes in patients with hemophilia A\n2. Emphasize the importance and clinical benefits of rFVIII-Fc in joint and bone health.\n3. Compare the clinical outcomes from 1 year before and after switching to EHL.\n4. Exploratory: Identify biomarkers that could provide more useful and convenient evaluations of joint and bone health. (Time-saving and easy to monitor)",[380],"Severe Hemophilia A Without Inhibitor","2024-04-08",{"date":383,"type":42},"2024-04-10",{"date":385,"type":42},"2023-07-14",{"date":387,"type":21},"2027-12-31",{"name":48,"class":49},{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":123,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":4},"100517095","effects-of-cognitive-behavioral-therapy-for-insomnia-in-nurses-with-post-covid-19-condition-100517095","NCT06013085","Effects of Cognitive-behavioral Therapy for Insomnia in Nurses With Post Covid-19 Condition","CBT-I","Inclusion Criteria:\n\n* nurses with post COVID-19 condition\n\nExclusion Criteria:\n\n* history of sleep apnea, narcolepsy, pregnant, seizure, with pacemaker",{"count":397,"type":21},100,[98],"Background: Neuropsychiatric conditions, such as insomnia, anxiety, depression, and pain are the most common symptoms experienced by nurses after acute infection of COVID-19. Although medication can assist nurses to improve these symptoms simultaneously in a short period of time, they are at risk of overuse of benzodiazepine hypnotics. Previous research supports the usefulness of cognitive behavioral therapy for insomnia (CBT-I) as self-management strategies in adults with insomnia, anxiety, depression, and pain. However, their effects on post COVID-19 condition have not been researched, and no previous head-to-head study compared the effects on these two approaches on insomnia and neuropsychiatric symptoms.\n\nAim: To investigate the effects of CBT-I on insomnia, anxiety, depression, and pain in nurses with post COVID-19 condition.\n\nMethods: In this two-arm, parallel randomized controlled trial, 100 participants will be 1:1 randomly assigned to one of two groups (CBT-I and control). The intervention phase will last 6 weeks, followed by a three-month follow-up. Primary outcomes are insomnia severity and sleep quality, whereas anxiety, depression, pain, and health-related quality of life are secondary outcomes. These variables will be assessed before and after the intervention, and at 1, 2, and 3 months after the end of the intervention. Additionally, discontinuing benzodiazepine hypnotics will be measured at 3 months after the end of the intervention.\n\nDiscussion: This study will provide evidence of the effects of CBT-I on improving insomnia, anxiety, depression, and pain among nurses with post COVID-19 condition. Results could also enhance means by which to discontinue benzodiazepine hypnotics.",[401],"Cognitive Behavioral Therapy","2023-08-25",{"date":404,"type":42},"2023-08-28",{"date":406,"type":21},"2023-09-01",{"date":244,"type":21},{"name":48,"class":49},""]